The 2026 Nobel Prize in Physiology or Medicine, announced on 5 October, went to Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg "for their discoveries concerning light-gated ion channels and optogenetics." Two days later, a clinical trial showed what the technique can mean for patients.
Key facts
Hegemann and Nagel discovered channelrhodopsin, a light-sensitive protein in a single-celled alga. Deisseroth turned it into a switch that lets scientists turn nerve cells on and off with light.
In the PIONEER trial, published in the New England Journal of Medicine on 7 October, 10 legally blind people with retinitis pigmentosa received a gene that makes surviving retinal cells sensitive to light.
Seven of the 10 became more sensitive to light, and six reached gains considered clinically meaningful. Participants wear goggles that turn what a camera sees into light patterns.
Some participants got better at finding and reaching for objects, and brain recordings confirmed that visual signals were reaching the visual cortex.
Why it matters
Retinitis pigmentosa affects more than 1.5 million people worldwide. A tool that began as basic research on algae is now giving some patients back a small but real measure of vision.
Worth noting
This is not a cure. The trial was small, the gains are limited, participants cannot read with the system, and it relies on special goggles. Most side effects were mild or moderate, and larger studies are needed.